A detailed history of Mai Capital Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mai Capital Management holds 2,418 shares of VRTX stock, worth $1.09 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,418
Previous 3,638 33.53%
Holding current value
$1.09 Million
Previous $1.71 Million 34.08%
% of portfolio
0.01%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$460.0 - $505.78 $561,200 - $617,051
-1,220 Reduced 33.53%
2,418 $1.12 Million
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $100,952 - $124,781
257 Added 7.6%
3,638 $1.71 Million
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $271,113 - $296,643
665 Added 24.48%
3,381 $1.41 Million
Q4 2023

Feb 09, 2024

BUY
$343.0 - $410.68 $72,716 - $87,064
212 Added 8.47%
2,716 $1.11 Million
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $122,082 - $130,848
-361 Reduced 12.6%
2,504 $870,000
Q2 2023

Aug 02, 2023

SELL
$314.42 - $351.91 $53,451 - $59,824
-170 Reduced 5.6%
2,865 $1.01 Million
Q1 2023

May 10, 2023

BUY
$283.23 - $323.1 $1,982 - $2,261
7 Added 0.23%
3,035 $956,000
Q4 2022

Feb 09, 2023

BUY
$285.76 - $321.48 $134,307 - $151,095
470 Added 18.37%
3,028 $874,000
Q3 2022

Nov 15, 2022

BUY
$273.83 - $305.53 $71,743 - $80,048
262 Added 11.41%
2,558 $741,000
Q2 2022

Jul 19, 2022

SELL
$234.96 - $292.55 $21,381 - $26,622
-91 Reduced 3.81%
2,296 $647,000
Q1 2022

May 10, 2022

BUY
$221.42 - $260.97 $137,723 - $162,323
622 Added 35.24%
2,387 $623,000
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $19,117 - $24,132
108 Added 6.52%
1,765 $388,000
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $300,563 - $336,354
1,657 New
1,657 $301,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mai Capital Management Portfolio

Follow Mai Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.